After radical surgery for gastric cancer patients, according to the pathological type and immuno-biochemical results, further targeted therapy can be taken, which can effectively improve the therapeutic effect of gastric cancer patients after surgery, prolong the survival period and cure rate of the patients appropriately, and prevent distant metastasis and recurrence, which all play a certain therapeutic effect. For gastric cancer patients with clinical manifestation of HER2-positive, they can take the application of Herceptin for targeted therapy, and can obtain certain satisfactory effect after operation. As for the targeted drugs for gastric cancer, clinicians can choose Apatinib and targeted monoclonal antibody drugs, which can effectively inhibit the growth of gastric cancer cells and stabilize the condition. Therefore, the specific use of drugs should be combined with the patient’s condition, and it is best to carry out the treatment under the guidance of doctors.